Wall Street Zen Upgrades Shuttle Pharmaceuticals (NASDAQ:SHPH) to Sell

Shuttle Pharmaceuticals (NASDAQ:SHPH) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Performance

Shuttle Pharmaceuticals stock opened at $2.50 on Friday. The business’s fifty day moving average is $3.64 and its two-hundred day moving average is $4.13. The firm has a market cap of $2.68 million, a P/E ratio of -0.05 and a beta of -1.01. Shuttle Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $30.83.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .